Introduction
============

Gastroesophageal reflux disease (GERD), a common disease in which the stomach contents reflux into the esophagus, can cause esophagitis and daily life disorders. In North American studies, the GERD prevalence has been estimated as 18.1-27.8%, in European studies, 8.8-25.9%, and in Asian studies, 2.5-7.8%.^[@ref1]^ Although the prevalence of GERD has been lower in Asian than in Western populations, it has recently shown a rapidly increasing trend in Asia.^[@ref2]^ In Korea, the prevalence of GERD has increased from 4.6% to 7.3% between 2005 and 2008.^[@ref3],[@ref4]^

Because of the high prevalence and chronic nature of the disease, the impact of GERD on health care utilization and medical expenditure have been considerable.^[@ref5]^ In the United States (US), GERD is the most common gastrointestinal (GI) disease diagnosed in outpatient clinic visits,^[@ref6]^ and the medical costs were estimated to be \$15-20 billion per year.^[@ref7]^ In Korea, the number of clinic patients treated for GERD more than tripled from 2000 to 2011 (n = 990 000 in 2000 and n = 3 110 000 in 2011). The medical expenditure for GERD was approximately \$1.5 billion out of the \$36 billion expended for all GI disease in 2007.^[@ref8]^ Considering the trend of increasing prevalence, the expenditures for GERD can be expected to rise much higher.

Treatment for GERD includes lifestyle modification, medications such as antacids or proton pump inhibitors (PPIs), and antireflux surgery (ARS). Most patients with GERD receive PPIs to manage the symptoms of the disease.^[@ref9]^ Unfortunately, GERD symptoms reportedly persist in 30-60% of patients who receive PPIs.^[@ref8],[@ref10]^ Moreover, considerable empirical evidence has accumulated about various adverse events associated with long-term use of PPIs, such as osteoporosis, ischemic heart disease, chronic kidney injury, and dementia.^[@ref11]^ Despite the widespread use of PPIs, prevalence data on the long-term use of PPIs in Korea have been lacking.

ARS is an alternative for the treatment of GERD in cases of severe disease requiring long-term use of PPIs and recurrent or intractable disease.^[@ref12]^ The clinical guidelines for surgical and medical treatments for GERD are well-established,^[@ref12]^ and the utilization of ARS is substantial in Western countries.^[@ref13]-[@ref15]^ However, ARS has been rarely performed in Korea.

In order to improve treatment effectiveness and reduce unnecessary medical expenditures, it is important to explore the treatment patterns of refractory GERD in Korea and estimate their medical costs. Thus, we aim to use nationally representative data to investigate: (1) numbers of patients undergoing ARS and receiving long-term treatment with PPIs, (2) PPI prescription patterns among long-term PPI users, and (3) medical expenditures according to the treatment type (ARS and PPIs).

Materials and Methods
=====================

Study Subjects
--------------

We conducted a cross-sectional analysis using nationally representative sample data provided by the Health Insurance Review and Assessment Service (HIRA). The HIRA claims data, collected for reimbursement of national healthcare insurance and medical aid, include patients' diagnoses, treatment, procedures, surgical history, and prescription drugs. HIRA provides several datasets using different sampling strategies to ensure dataset reliability and representativeness of the specific target population. The HIRA-National Patient Sample (NPS), a random selection of 3.0% of all patients, represents the total population that visits medical institutions each year. The HIRA-National Inpatient Sample (NIS), a random selection of 13.0% of total inpatients annually, is suitable for analysis of inpatients.^[@ref8],[@ref9]^ We used the HIRA-NPS for the analysis of medication therapy for GERD, and we used the HIRA-NIS for the analysis of GERD surgery. The NPS from 2012 to 2016 included 11 cases of surgical treatment for GERD; the NIS from this period included 40 such cases.

[Figure 1](#F1){ref-type="fig"} presents the study population selection procedure. For this study, we selected 86 936 participants for the medication group and 40 participants for the surgery group. The NPS and NIS were released after anonymization and de-identification of the data; therefore, informed consent could not be obtained from participants individually. This study was approved by the Institutional Review Board of Kosin University Gospel Hospital (IRB No. KUGH 2018-02-013).

Variables
---------

The surgical group was composed of patients diagnosed with GERD who underwent fundoplication. The diagnosis of GERD was defined according to the "International Classification of Disease, 10th edition, clinical modification (ICD-10-CM)" as follows: K20.0, K20.9, K21.0, and K21.9. Fundoplication was confirmed using the corresponding surgical codes.

The medication group included patients with refractory GERD who required medication with PPIs for more than 12 weeks to treat GERD symptoms. A consecutive prescription was defined as having the next prescription of PPIs within 7 days of the last date of the prescription period. We calculated the average prescribed daily dose (PDD) of PPIs during the primary consecutive prescription period of 12 weeks and then categorized these doses into 3 groups: \< standard dose, standard to \< double dose, and ≥ double dose.

Medical expenditure was defined as the total costs of GERD treatment in the medical care institute covered by the insurer and beneficiary. Average monthly costs for each group were calculated as total medical costs divided by the number of follow-up months to account for the difference in observation time for GERD treatments. The follow-up period for the surgery group was calculated from the day of operation to December 31 in each year. In the medication group, the follow-up time was counted from the end date of the primary consecutive prescription of 12 weeks to December 31. Medical costs were presented as US dollars, which were calculated based on an exchange rate of Korean Republic won 1000 = \$1.

Health status at baseline was measured using the Charlson Comorbidity Index (CCI),^[@ref10]^ which is scored using 17 types of chronic diseases: myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, moderate or severe liver disease, non-complicated diabetes, complicated diabetes, hemiplegia or paraplegia, renal disease, any malignancy except skin cancer, metastatic solid tumor, and acquired immunodeficiency syndrome. These chronic diseases were defined based on the ICD-10 codes in the medical treatment data and then each disease was weighted based on its severity.

Analysis
--------

We analyzed the prevalence and 95% confidence intervals (CIs) of patients who were prescribed PPIs for more than 12 weeks from 2012 to 2016. The overall prevalence was calculated based on the population over age 20 years in Korea and standardized by age and sex using the distribution of the 2015 census population in Korea. The prevalence was also analyzed by sex and age subgroups. The Cochran-Armitage trend test was conducted to confirm the increasing prevalence. To estimate the number of patients in Korea, we calculated the weighted number of patients prescribed PPIs more than 12 weeks using the sampling weight in the HIRA-NPS.

The mean and standard deviation of the medical costs were estimated for inpatients, outpatients, and prescribed drug costs (PPI costs and other drug costs). We estimated the mean total medical costs in the surgery group and this was split into 2 parts according to the follow-up time of 3 months post-operation to distinguish the cost of surgery from that of GERD treatment. For the medication group, we calculated the mean costs according to the PDD of PPIs.

A generalized linear model (GLM) was used to compare the medical expenditures of the medication and surgery groups after adjusting for confounding variables such as demographic information and comorbidities. Log link and gamma distributions were selected in the GLM to reflect the right-skewed distribution of medical expenditure.^[@ref11]^ We considered the follow-up month as an offset variable because participants had different follow-up periods. The cost ratios and 95% CIs using the GLM are calculated. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC, USA).

Results
=======

[Table 1](#T1){ref-type="table"} shows the distributions of the demographics and comorbidities for the medication and surgery groups. The number of GERD patients who received PPIs for at least 12 weeks was 86 936, which corresponded to 9.1% of the GERD patients receiving PPIs (n = 958 213), 5.5% of the total number of GERD patients (n = 1 572 839), and 1.6% of the total population aged 20 and over (n = 5 611 025). The numbers of male and female subjects were similar in both groups, but there were more subjects with older age and a high CCI score in the medication group than in the surgery group.

[Figure 2](#F2){ref-type="fig"} presents the age- and sex-standardized prevalence in the adult population and estimated numbers of patients prescribed PPIs for more than 12 weeks in the 5-year study period. The prevalence increased from 2012 to 2016 (11.8 in 2012, 19.1 in 2016, per 1000 people), which was statistically significant in the Cochran-Armitage trend test (P for trend \< 0.001). As the prevalence increased, the numbers of patients also rose from 402 000 in 2012 to 736 000 in 2016.

[Figure 3](#F3){ref-type="fig"} shows the prevalence of patients prescribed PPIs more than 12 weeks by age and sex. The prevalence was higher in women than in men, which tended to increase similarly. The prevalence was notably higher in adults aged over 60 years than in those aged 20-50 years. The results of the Cochran-Armitage trend test showed that the prevalence of all sexes and ages showed a statistically significant increase in the 5-year study period.

[Table 2](#T2){ref-type="table"} presents the proportions of PDD levels during the primary 12-week consecutive prescription period of PPIs in the medication group. The percentages of patients prescribed PPIs below the standard dose, between the standard and double doses, and at or above the double dose were 85.6-89.1%, 10.4-13.5%, and 0.5-0.9%, respectively. Hence, the proportion of patients prescribed PPIs below the standard dose decreased from 2012 to 2016, whereas the proportion of patients prescribed PPIs at or above the double dose increased almost 2-fold.

[Table 3](#T3){ref-type="table"} shows the average costs for inpatients, outpatients, PPIs, and other GERD drugs according to therapy type. The medical costs of the surgery group are presented according to the 2 periods (based on a cutoff of 90 days post-operation), which were considered to reflect the costs of fundoplication and of GERD treatment after surgery, respectively. The total medical costs within 90 days of and over 90 days after surgery were \$2072 per month (\$6215 for 3 months) and \$108 per month, respectively. Average medical costs for the medication group were \$163 per month. Patients prescribed PPIs below the standard dose, between the standard and double doses, and at or above the double dose spent \$158, \$192, and \$255 per month on GERD treatment, respectively.

Additionally, we analyzed the medical costs according to age, sex, and CCI score because the general distributions between the surgery and medication groups were very different. In both the surgery and medication groups, the medical costs were higher in patients with higher CCI scores than in their counterparts with lower scores. However, the medical costs by age groups showed different patterns in the surgery and medication groups. Young adults under age 40 years paid higher costs for GERD treatment compared with middle and older adults in the medication group; whereas, in the surgery group, medical costs were greater in middle and older adults than in young adults ([Supplementary Table 1](#S1){ref-type="supplementary-material"}).

[Table 4](#T4){ref-type="table"} presents the cost ratios and 95% CIs for total monthly medical costs for GERD treatment according to therapy type after adjustment for demographics and comorbidities. The medical costs of the surgery group were analyzed in separate GLMs based on 90 days from operation. Total monthly medical costs within 90 days of surgery were 13 times (cost ratio, 12.73; 95% CI, 9.19-17.64) and 16 times (cost ratio, 16.19; 95% CI, 12.03-21.78) higher than those of the medication group in the univariate and multivariable models, respectively. When we analyzed the medical costs over 90 days post-operation, there was no statistically significant difference between the medication and surgery groups. We also constructed GLMs using total surgery cases and matching medication samples. Medication samples were selected through 1:4 matching to the surgery cases based on age, sex, and CCI score. Then, we confirmed similar results with the main analysis of [Table 4](#T4){ref-type="table"} ([Supplementary Tables 2 and 3](#S1){ref-type="supplementary-material"}).

Discussion
==========

This study provides clear findings of the recent pattern of treatment for GERD patients in Korea. First, a substantial number of GERD patients received PPI medication for at least 12 weeks and this treatment has gradually increased from 2012 to 2016. Over the same period, the number of patients who underwent ARS was significantly lower than that of patients treated with PPIs. Second, based on the PDD calculation for the initial 12 weeks, we found that approximately 10.0% of long-term PPI users were prescribed more than the standard dose and the proportion also increased with time. Third, medical costs for GERD treatment were 16 times higher in the surgery group than in the medication group within 90 days of ARS; however, medical costs were not significantly different between the surgery and medication groups after 90 days post-ARS.

The 5-year prevalence of refractory GERD was assumed to be approximately 1.6% using nationally representative claims data. Although the definition of refractory GERD is controversial,^[@ref16]^ it is generally described as non-responsiveness of symptoms to PPIs during a treatment period of at least 12 weeks.^[@ref17]^ Thus, we estimated the prevalence based on the definition of refractory GERD, which is persistent symptoms with long-term use of PPIs for more than 12 weeks. There have been no comparable Korean data on the prevalence of refractory GERD. Previous studies in Korea showed that the GERD prevalence was 7.3%,^[@ref3]^ and the proportion of patients with non-responsive GERD ranged from 9.1% to 26.9%.^[@ref18],[@ref19]^ These results indicate that approximately 0.7-2.0% of the total population may have refractory GERD, which is consistent with our results.

In this study, we also observed that the prevalence of refractory GERD, as well as the average PDD of PPIs, increased over time. Numerous empirical studies have suggested the potential adverse effects of long-term use of PPIs, including hypomagnesemia, Clostridium difficile-associated diarrhea, vitamin B12 deficiency, fracture, and dementia.^[@ref11],[@ref20]^ Surgical treatment may be offered as a treatment option or alternative in patients who are concerned about long-term complications of PPI use.^[@ref21]^

Refractory GERD is one of the most important indications for ARS. Despite some inconsistencies in ARS indications, 2 traditional guidelines, those of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and American Gastroenterology Association (AGA), have commonly recommended that refractory GERD is an indication for ARS.^[@ref12],[@ref21]^ Frazzoni et al^[@ref22]^ reported good results with surgical treatment of refractory GERD diagnosed by subgrouping according to impedance-pH monitoring. PPI-responsive GERD is also an indication for ARS. Although the opinions of the AGA and SAGES differ for PPI-responsive GERD, the results of the Long-Term Usage of Esomeprazole vs Surgery for Treatment of Chronic GERD (LOTUS) trial show that heartburn remission is maintained at 5 years post-surgery.^[@ref23]^

Nevertheless, ARS has been rarely performed in Korea. We found only 40 cases of ARS among 1 572 839 patients with GERD in our analysis. However, in the US alone, the number of ARS was estimated to be 20 000 annually.^[@ref15]^ Another US study reported that 0.05% of patients with GERD underwent ARS.^[@ref14]^ Very low rates of ARS in Korea might be related to concerns about postoperative complications such as dysphagia and flatulence or the lack of awareness of the therapeutic effect of ARS. However, the surgical outcomes, including relief of GERD symptoms (typical and atypical), in Korea were comparable to those in Western countries.^[@ref24],[@ref25]^ Moreover, even if patients took PPIs again after ARS, the PPI response rate was significantly improved.^[@ref26]^

Our results reveal that medical costs for PPI therapy were high (average monthly cost = \$163). Furthermore, we found that initial medical costs were much higher in the surgery group than in the medication group, but maintenance costs were not significantly different between the groups. Several previous studies showed that the total costs of ARS, including the inpatient care and surgery fees, were high at the beginning of treatment, but gradually decreased.^[@ref27]-[@ref29]^

This study has several limitations. First, our data contained a very small number of surgical cases; thus, the results of cost comparisons between surgery and medication need cautious interpretation. Second, the clinical results of each treatment (eg, symptom change and quality of life) were not investigated, because we used secondary data extracted from a national health insurance database. Thus, refractory GERD was defined based on only PPI treatment duration, which may result in over- or under-estimation of prevalence. Third, we analyzed the cross-sectional data per year; therefore, our results could not demonstrate changes in treatment patterns and medical costs over time for more than one year.

To the best of our knowledge, no previous study has reported the national prevalence and treatment patterns of refractory GERD in Korea. Considering the increasing prevalence of long-term use and the high medical costs for PPIs, medical expenditures for GERD can increase in the future. Thus, in order to reduce medical expenditures and improve treatment effectiveness, further studies including sufficient numbers of surgery cases, clinical assessment of efficacy, and long-term follow-up comparing medical and surgical treatments for GERD should be conducted.
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###### 

General Distribution of Study Participants: The Health Insurance Review and Assessment Service-National Patient Sample and the Health Insurance Review and Assessment Service-National Inpatient Sample (2012-2016)

  Variables   HIRA-NPS (2012-2016)   HIRA-NIS (2012-2016)        
  ----------- ---------------------- ---------------------- ---- ---------------
  Total       86 936                 100.00 (0.00)          40   100.00 (0.00)
  Sex                                                            
  Men         39 388                 45.31 (0.17)           20   50.00 (8.01)
  Women       47 548                 54.69 (0.17)           20   50.00 (8.01)
  Age (yr)                                                       
  20-39       3046                   3.50 (0.06)            16   40.00 (7.84)
  40-59       26 967                 31.02 (0.16)           14   35.00 (7.64)
  ≥ 60        56 923                 65.48 (0.16)           10   25.00 (6.93)
  CCI score                                                      
  0-1         21 011                 24.17 (0.15)           12   30.00 (7.34)
  2-3         30 931                 35.58 (0.16)           23   57.50 (7.92)
  ≥ 4         34 994                 40.25 (0.17)           5    12.50 (5.30)

HIRA-NIS, the Health Insurance Review and Assessment Service-National Inpatient Sample; HIRA-NPS, the Health Insurance Review and Assessment Service-National Patient Sample; PPI, proton pump inhibitors; CCI, Charlson Comorbidity Index.

###### 

Distributions of the Prescribed Daily Dose of Proton Pump Inhibitors in Patients Prescribed Proton Pump Inhibitors for More Than 12 Weeks

  Variables                    2012     2013            2014     2015            2016                                                       
  ---------------------------- -------- --------------- -------- --------------- -------- --------------- -------- --------------- -------- ---------------
  PDD of PPIs                  12 059   100.00 (0.00)   12 802   100.00 (0.00)   18 360   100.00 (0.00)   21 643   100.00 (0.00)   22 072   100.00 (0.00)
  \< standard dose             10 747   89.12 (0.28)    11 493   89.78 (0.27)    16 178   88.12 (0.24)    18 871   87.19 (0.23)    18 893   85.60 (0.24)
  Standard to \< double dose   1249     10.36 (0.28)    1249     9.76 (0.26)     2089     11.38 (0.23)    2630     12.15 (0.22)    2978     13.49 (0.23)
  ≥ double dose                63       0.52 (0.07)     60       0.47 (0.06)     93       0.51 (0.05)     142      0.66 (0.05)     201      0.91 (0.06)

PDD, prescribed daily dose; PPI, proton pump inhibitor.

###### 

Medical Costs of Gastroesophageal Reflux Disease Treatment in the Medication and Surgery Groups (Unit: Dollars)

  Variables                               n        A. Inpatient costs   B. Outpatient costs   C. PPI costs   D. Other drug costs   E. Follow-up months   Total monthly costs (A + B + C + D)/E
  --------------------------------------- -------- -------------------- --------------------- -------------- --------------------- --------------------- ---------------------------------------
  Surgery group                                                                                                                                          
  Total                                   40       4591.7 (403.90)      232.4 (42.83)         37.7 (12.78)   200.0 (111.51)        6.7 (0.61)            1423.9 (259.22)
  Number of days from surgery                                                                                                                            
  ≤ 90                                    40       4509.7 (390.74)      99.1 (19.57)          13.1 (4.26)    153.5 (110.67)        2.6 (0.11)            2071.6 (240.17)
  \> 90[a](#t3fn1){ref-type="table-fn"}   30       109.4 (109.42)       177.7 (48.37)         32.8 (14.22)   62.1 (23.41)          5.4 (0.51)            107.7 (59.99)
  Medication group                                                                                                                                       
  Total                                   86 936   540.2 (10.24)        359.5 (7.24)          156.6 (0.36)   455.8 (2.47)          9.3 (0.01)            162.7 (1.35)
  PDD of PPIs                                                                                                                                            
  \< standard                             76 182   513.2 (10.66)        348.4 (7.86)          148.3 (0.34)   450.8 (2.53)          9.3 (0.01)            158.1 (1.44)
  standard to \< double                   10 195   702.7 (33.59)        426.0 (18.49)         213.9 (1.45)   495.6 (9.04)          9.4 (0.03)            191.7 (4.03)
  ≥ double                                559      1251.3 (215.52)      658.0 (85.56)         235.4 (9.49)   412.5 (28.29)         9.5 (0.12)            254.6 (23.30)

Only subjects who passed 3 months after surgery in each year were analyzed.

PPI, proton pump inhibitor; PDD, prescribed daily dose.

Data are presented as mean (SE).

###### 

Generalized Linear Models for Total Monthly Costs According to Medication or Surgery

  Variables       Medical expenditure within 90 days[a](#t4fn1){ref-type="table-fn"}   Medical expenditure after 90 days[b](#t4fn2){ref-type="table-fn"}                                                                                     
  --------------- -------------------------------------------------------------------- ------------------------------------------------------------------- --------------------- ---------- ------------------ ---------- ------------------ ----------
  Therapy group                                                                                                                                                                                                                              
  Medication      Reference                                                            \-                                                                  Reference             \-         Reference          \-         Reference          \-
  Surgery         12.73 (9.19-17.64)                                                   \< 0.001                                                            16.19 (12.03-21.78)   \< 0.001   0.90 (0.58-1.40)   0.648      0.84 (0.56-1.25)   0.392
  Sex                                                                                                                                                                                                                                        
  Men             Reference                                                            \-                                                                  Reference             \-         Reference          \-         Reference          \-
  Women           0.84 (0.83-0.85)                                                     \< 0.001                                                            0.91 (0.89-0.92)      \< 0.001   0.84 (0.83-0.85)   \< 0.001   0.91 (0.90-0.92)   \< 0.001
  Age (yr)                                                                                                                                                                                                                                   
  20-39           Reference                                                            \-                                                                  Reference             \-         Reference          \-         Reference          \-
  40-59           0.88 (0.84-0.91)                                                     \< 0.001                                                            0.73 (0.70-0.76)      \< 0.001   0.88 (0.84-0.91)   \< 0.001   0.73 (0.70-0.76)   \< 0.001
  60-79           0.94 (0.90-0.97)                                                     0.001                                                               0.68 (0.66-0.71)      \< 0.001   0.94 (0.90-0.97)   0.001      0.68 (0.66-0.71)   \< 0.001
  ≥ 80            1.04 (0.99-1.08)                                                     0.097                                                               0.72 (0.69-0.75)      \< 0.001   1.04 (0.99-1.08)   0.097      0.72 (0.69-0.75)   \< 0.001
  CCI score                                                                                                                                                                                                                                  
  0-1             Reference                                                            \-                                                                  Reference             \-         Reference          \-         Reference          \-
  2-3             1.48 (1.45-1.50)                                                     \< 0.001                                                            1.51 (1.48-1.53)      \< 0.001   1.48 (1.45-1.50)   \< 0.001   1.51 (1.48-1.53)   \< 0.001
  ≥ 4             3.27 (3.22-3.33)                                                     \< 0.001                                                            3.39 (3.33-3.44)      \< 0.001   3.27 (3.22-3.33)   \< 0.001   3.39 (3.33-3.44)   \< 0.001

Models included the medical expenditure within 90 days of fundoplication in the surgery group.

Models included the medical expenditure from 90 days after fundoplication in the surgery group.

CR, cost ratio; CCI, Charlson Comorbidity Index.

[^1]: Susan Park and Jin-Won Kwon equally contributed to this study.
